2009-11-01

Vice President:

Professor of Medicine and Director, Division of Hematology, Epstein Chair in Cell Therapy and Transplantation, University of Toronto; Director, Cell Therapy Program, Princess Margaret Hospital, Toronto, ON

Dr. Keating’s clinical and research interests focus on anti-cancer cell therapy, blood and marrow transplantation, leukemia, lymphoma, and cell-based tissue regeneration. He has conducted laboratory, translational, and clinical research in cell therapy, normal and leukemic hematopoiesis, and the biology and clinical application of mesenchymal stromal cells. Dr. Keating will serve as vice president in 2010, becoming president-elect in 2011, and then president in 2012.

Councillors:

Kraft Family Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA

Dr. Anderson serves as chief of the Division of Hematologic Neoplasia, director of the Lipper Myeloma Center and Lebow Institute for Myeloma Therapeutics, and vice chair of the Joint Program in Transfusion Medicine at DFCI. Novel biologically based therapies for multiple myeloma is his area of research. Dr. Anderson will serve a fouryear term.

Wellcome Professor of Medicine and Chief, Division of Hematology, Duke University Medical Center, Durham, NC

Dr. Telen is recognized as an expert in the biochemistry and molecular genetics of blood group antigens and the pathophysiological mechanisms of vaso-occlusion in sickle cell disease. She is the director of the Duke Comprehensive Sickle Cell Center. Dr. Telen will serve a four-year term.

Vice President for Research, New York Blood Center, New York, NY

Dr. Narla is the Director of the Lindsley F. Kimball Research Institute and heads the Laboratory of Red Cell Physiology at New York Blood Center. His primary research focus is the study of the structural organization of blood cell membranes in health and disease and regulation of blood cell production. Dr. Narla will serve a one-year term.

back to top